Biological
Tumor Infiltrating Lymphocytes
Tumor Infiltrating Lymphocytes is a biological therapy with 6 clinical trials. Currently 1 active trials ongoing.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Completion Rate
0%(0/3)
Active Trials
1(17%)
Terminated
3(50%)
Phase Distribution
Ph phase_1
1
17%
Ph early_phase_1
3
50%
Ph phase_2
2
33%
Phase Distribution
4
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
3(50.0%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 3 finished
Non-Completion Rate
100.0%
3 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Terminated(3)
Other(1)
Detailed Status
Terminated3
unknown1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 13 (50.0%)
Phase 11 (16.7%)
Phase 22 (33.3%)
Trials by Status
terminated350%
unknown117%
not_yet_recruiting117%
recruiting117%
Recent Activity
1 active trials
Showing 5 of 6
recruitingearly_phase_1
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
NCT05087745
not_yet_recruitingearly_phase_1
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
NCT05649618
terminatedearly_phase_1
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
NCT03526185
terminatedphase_2
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
NCT01369875
unknownphase_2
Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy
NCT00604136
Clinical Trials (6)
Showing 6 of 6 trials
NCT05087745Early Phase 1
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
NCT05649618Early Phase 1
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
NCT03526185Early Phase 1
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
NCT01369875Phase 2
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
NCT00604136Phase 2
Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy
NCT01369888Phase 1
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6